Article

Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through the Activation of Insulin-Like Growth Factor 1 Receptor

Akiko MurakamiDepartment of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan ; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, JapanFumiyuki TakahashiDepartment of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan ; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, JapanFariz NurwidyaDepartment of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan ; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, JapanIsao KobayashiDepartment of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan ; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, JapanKunihiko MinakataDepartment of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan ; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, JapanMuneaki HashimotoDepartment of Molecular and Cellular Parasitology, Juntendo University, Graduate School of Medicine, Tokyo, JapanTakeshi NaraDepartment of Molecular and Cellular Parasitology, Juntendo University, Graduate School of Medicine, Tokyo, JapanMotoyasu KatoDepartment of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan ; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, JapanKen TajimaDepartment of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan ; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, JapanNaoko ShimadaDepartment of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan ; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, JapanShin‐ichiro IwakamiJuntendo University Shizuoka Hospital, Shizuoka, JapanMariko MoriyamaPharmaceutical Research and technology institute, Kinki University, School of Medicine, Osaka, JapanHiroyuki MoriyamaPharmaceutical Research and technology institute, Kinki University, School of Medicine, Osaka, JapanFumiaki KoizumiKazuhisa TakahashiDepartment of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan ; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, Japan

2014en

ABI

Abstract

Accumulating evidence indicates that a small population of cancer stem cells (CSCs) is involved in intrinsic resistance to cancer treatment. The hypoxic microenvironment is an important stem cell niche that promotes the persistence of CSCs in tumors. Our aim here was to elucidate the role of hypoxia and CSCs in the resistance to gefitinib in non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation. NSCLC cell lines, PC9 and HCC827, which express the EGFR exon 19 deletion mutations, were exposed to high concentration of gefitinib under normoxic or hypoxic conditions. Seven days after gefitinib exposure, a small fraction of viable cells were detected, and these were referred to as "gefitinib-resistant persisters" (GRPs). CD133, Oct4, Sox2, Nanog, CXCR4, and ALDH1A1-all genes involved in stemness-were highly expressed in GRPs in PC9 and HCC827 cells, and PC9 GRPs exhibited a high potential for tumorigenicity in vivo. The expression of insulin-like growth factor 1 (IGF1) was also upregulated and IGF1 receptor (IGF1R) was activated on GRPs. Importantly, hypoxic exposure significantly increased sphere formation, reflecting the self-renewal capability, and the population of CD133- and Oct4-positive GRPs. Additionally, hypoxia upregulated IGF1 expression through hypoxia-inducible factor 1α (HIF1α), and markedly promoted the activation of IGF1R on GRPs. Knockdown of IGF1 expression significantly reduced phosphorylated IGF1R-expressing GRPs under hypoxic conditions. Finally, inhibition of HIF1α or IGF1R by specific inhibitors significantly decreased the population of CD133- and Oct4-positive GRPs, which were increased by hypoxia in PC9 and HCC827 cells. Collectively, these findings suggest that hypoxia increased the population of lung CSCs resistant to gefitinib in EGFR mutation-positive NSCLC by activating IGF1R. Targeting the IGF1R pathway may be a promising strategy for overcoming gefitinib resistance in EGFR mutation-positive NSCLC induced by lung CSCs and microenvironment factors such as tumor hypoxia.

Identifiers

DOI: 10.1371/journal.pone.0086459

Citations and references

Cited by 20 references

Metrics — AkademScholar